title: Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years.
abstract: OBJECTIVE
  To generate estimates of the association between markers of ovarian aging and natural fertility in a community sample at risk for ovarian aging.
  
  
  METHODS
  Women aged 30-44 years with no history of infertility who had been trying to conceive for less than 3 months provided early-follicular phase serum and urine (N=100). Subsequently, these women kept a diary to record menstrual bleeding and intercourse and conducted standardized pregnancy testing for up to 6 months. Serum was analyzed for estradiol, follicle-stimulating hormone (FSH), antimüllerian hormone, and inhibin B. Urine was analyzed for FSH and estrone 3-glucuronide. Diary data on menstrual cycle day and patterns of intercourse were used to calculate day-specific fecundability ratios.
  
  
  RESULTS
  Sixty-three percent of participants conceived within 6 months. After adjusting for age, 18 women (18%) with serum antimüllerian hormone levels of 0.7 ng/mL or less had significantly reduced fecundability given intercourse on a fertile day compared with women with higher antimüllerian hormone levels (fecundability ratio 0.38; 95% confidence interval [CI] 0.08-0.91). The day-specific fecundability for women with early-follicular phase serum FSH values greater than 10 milli-international units/mL compared with women with lower FSH levels was also reduced, although nonsignificantly (11% of women affected; fecundability ratio 0.44; 95% CI 0.08-1.10). The association with urinary FSH was weaker (27% women affected; fecundability ratio 0.61; 95% CI 0.26-1.26), and the associations for the other markers were weaker still.
  
  
  CONCLUSIONS
  Early-follicular phase antimüllerian hormone appears to be associated with natural fertility in the general population.
  
  
  METHODS
  II.
authors.affiliation: From the Departments of Obstetrics and Gynecology and Biostatistics, University of North Carolina, Chapel Hill, North Carolina; the National Institute for Occupational Safety and Health, Cincinnati, Ohio; the Department of Obstetrics and Gynecology and Preventive Medicine, University of Southern California, Los Angeles, California; and the Epidemiology Branch, National Institute of Environmental Health Science/National Institutes of Health, Research Triangle Park, North Carolina.
authors.forename: Anne Z
authors.initials: AZ
authors.lastname: Steiner
authors.forename: Amy H
authors.initials: AH
authors.lastname: Herring
authors.forename: James S
authors.initials: JS
authors.lastname: Kesner
authors.forename: Juliana W
authors.initials: JW
authors.lastname: Meadows
authors.forename: Frank Z
authors.initials: FZ
authors.lastname: Stanczyk
authors.forename: Steven
authors.initials: S
authors.lastname: Hoberman
authors.forename: Donna D
authors.initials: DD
authors.lastname: Baird
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D016001:Confidence Intervals; D004958:Estradiol / Q000097:blood*; D005260:Female; D005298:Fertility / Q000502:physiology; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007265:Inhibins / Q000097:blood*; D008423:Maternal Age; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D012307:Risk Factors
chemical_list: D015415:Biomarkers; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone